<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38389261</article-id><article-id pub-id-type="pmc">PMC467012</article-id>
<article-id pub-id-type="publisher-id">IJO-72-404</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_772_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of Tenon duplication with dura mater covering technique for Ahmed glaucoma valve implantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Erol</surname><given-names>Mehmet Akif</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Demirdizen</surname><given-names>Duygu &#x000d6;ren</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>&#x0015e;im&#x0015f;ek</surname><given-names>T&#x000fc;lay</given-names></name><xref rid="aff2" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Y&#x00131;ld&#x00131;r&#x00131;m</surname><given-names>Nilg&#x000fc;n</given-names></name><xref rid="aff2" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff1">Department of Ophthalmology, K&#x00131;rklareli University Faculty of Medicine, K&#x00131;rklareli, Turkey</aff><aff id="aff2"><label>1</label>Department of Ophthalmology, Eski&#x0015f;ehir Osmangazi University Faculty of Medicine, Eski&#x0015f;ehir, Turkey</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Prof. T&#x000fc;lay &#x0015e;im&#x0015f;ek, Department of Ophthalmology, Eski&#x0015f;ehir Osmangazi University, Faculty of Medicine, Eski&#x0015f;ehir, Turkey. E-mail: <email xlink:href="tulaysimsek@hotmail.com">tulaysimsek@hotmail.com</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>23</day><month>2</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S404</fpage><lpage>S408</lpage><history><date date-type="received"><day>21</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>12</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>To compare the efficacy and complications of Tenon duplication with dura mater covering technique for Ahmed glaucoma valve (AGV) implantation.</p></sec><sec id="st2"><title>Methods:</title><p>This retrospective study included 44 refractory glaucoma patients (44 eyes) who underwent AGV implantation from 2017 to 2020 in the Ophthalmology Clinic of Eski&#x0015f;ehir Osmangazi University Hospital and attended regular postoperative follow-ups. The patients were divided based on whether they underwent Tenon duplication technique (group 1: <italic toggle="yes">n</italic> = 20) or dura mater covering technique (group 2: <italic toggle="yes">n</italic> = 24) during surgery. The patients&#x02019; age, gender, systemic diseases, glaucoma type, pre-op intraocular pressure (IOP), and ocular surgeries were recorded. The groups were compared for IOP level control, early and late complications, postoperative antiglaucomatous medication requirements, glaucoma surgery requirements, presence of postoperative hypertensive phase (HP), and surgical success which was defined as an IOP &#x02265;5 and &#x02264;21 mmHg, with or without antiglaucoma medication.</p></sec><sec id="st3"><title>Results:</title><p>By the end of the mean follow-up (22.6 &#x000b1; 10.6 months), the success rates were 95% (group 1) and 96% (group 2). The groups showed no differences in postoperative complications, postoperative antiglaucomatous drugs&#x02019; onset time, additional glaucoma surgery, need for needling, presence of HP at 6 months postoperatively, and relationship between the glaucoma type and success rates (<italic toggle="yes">P</italic> values: 0.86, 0.9, 0.48, 0.12, 0.36, and 0.8, respectively). The IO<italic toggle="yes">P</italic> values at the last follow-up were 15.2 &#x000b1; 4.1 in group 1 and 14.7 &#x000b1; 4.8 in group 2. The IOP reduction rates showed no significant differences.</p></sec><sec id="st4"><title>Conclusion:</title><p>Since success and complications are similar in both Tenon duplication and dura mater covering technique, unique grafting materials may not be needed in AGV implantation surgery, except in special cases.</p></sec></abstract><kwd-group><kwd>Ahmed glaucoma valve implantation</kwd><kwd>dura mater covering technique</kwd><kwd>glaucoma</kwd><kwd>surgical technique</kwd><kwd>Tenon duplication technique</kwd></kwd-group></article-meta></front><body><p>Glaucoma, the second most important cause of blindness globally, is defined as a chronic optic neuropathy with progressive visual field defects. Although many risk factors, such as intraocular pressure (IOP),[<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref>] age,[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref>] genetic predisposition,[<xref rid="R5" ref-type="bibr">5</xref>] and vascular parameters,[<xref rid="R6" ref-type="bibr">6</xref><xref rid="R7" ref-type="bibr">7</xref><xref rid="R8" ref-type="bibr">8</xref>] have been identified for the development and progression of glaucoma, lowering IOP is the only scientifically proven method to slow progression.</p><p>IOP reduction in glaucoma patients can be achieved with medical, laser, or surgical treatment.[<xref rid="R9" ref-type="bibr">9</xref>] Medical treatment is usually the first choice because of the low rate of side effects, whereas laser or surgical option can be considered when the target IOP cannot be achieved.[<xref rid="R10" ref-type="bibr">10</xref>] Trabeculectomy, first described by Cairns in 1968, is considered the &#x0201c;gold standard&#x0201d; surgery for primary open-angle glaucoma.[<xref rid="R11" ref-type="bibr">11</xref>] However, the success rate of trabeculectomy, although high in the first years (70%&#x02013;92%), tends to decrease over time (42%&#x02013;90%), especially in secondary glaucomas.[<xref rid="R12" ref-type="bibr">12</xref><xref rid="R13" ref-type="bibr">13</xref><xref rid="R14" ref-type="bibr">14</xref><xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref>] Trabeculectomy is also greatly affected by the healing processes of the subconjunctival space in the bleb region. Therefore, modulation of recovery with intraoperative and postoperative antimetabolites (mitomycin C [MMC] and 5-fluorouracil [5-FU]) is an essential part of the procedure.[<xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref>]</p><p>Glaucoma drainage devices (GDDs) provide an alternative to traditional filtration surgery for the treatment of medical therapy&#x02013;resistant glaucomas and in patients with conjunctival problem.[<xref rid="R17" ref-type="bibr">17</xref>] As a working principle, shunting aqueous humor (AH) into the posterior subconjunctival space can prevent healing problems, especially in patients who have had previous glaucoma operation or conjunctival scar. Although the implant types vary, Ahmed glaucoma valve (AGV) is the most commonly used implant option.[<xref rid="R18" ref-type="bibr">18</xref>] AGV minimizes the risk of hypotonia by allowing AH above a certain pressure to flow through a silicone tube placed in the anterior chamber toward a pressure-controlled valve mechanism consisting of a polypropylene plate sutured to the sclera in the sub-Tenon space. The most important problems with AGV implantation are tube exposure, encapsulation, and postoperative hypertensive phase (HP).[<xref rid="R19" ref-type="bibr">19</xref>] Tube exposure usually occurs 3&#x02013;4 mm posterior to the corneoscleral limbus. Since this complication will have serious consequences leading to the loss of the eye, it should be treated quickly or preventive measures should be taken during surgery. Various covering techniques and graft materials have been developed to avoid tube exposure, including scleral tunnel, Tenon duplication, pericardial patch grafts, cadaveric dura mater, donor fascia lata graft, and preserved human sclera and cornea.[<xref rid="R20" ref-type="bibr">20</xref>] Although there are many comparative studies on tube covering techniques such as scleral flap and scleral tunnel techniques, pericardium, and lyophilized sclera, there are limited reports on dura mater covering and Tenon duplication techniques in AGV implantation surgery.[<xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>] The present study compares the Tenon duplication technique and dura mater covering in terms of postoperative complications and the success rate.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><p>This retrospective study included 44 eyes of 44 patients with refractory glaucoma who underwent AGV implant surgery between June 2017 and June 2020 in the Ophthalmology Department of Eski&#x0015f;ehir Osmangazi University Hospital. Due to the retrospective nature of the study, patients who were followed up regularly were included in the study. Cases followed for at least 1 year were included in the study. Pediatric cases, patients with irregular follow-up, and those who were not in compliance with their medications were excluded from the study. The patients were divided into a group that underwent the Tenon duplication technique (Group 1) and a group that underwent the dura mater covering technique during surgery (Group 2). Each patient&#x02019;s age, gender, systemic diseases, glaucoma type, previous surgical interventions, and IO<italic toggle="yes">P</italic> values were recorded. The two groups were compared for IOP, early and postoperative complications, needing antiglaucomatous medications and glaucoma surgery, and presence of an HP in the first 6 months postoperatively.</p><sec id="sec2-1"><title>Surgery</title><p>AGV (New World Medical Inc., Rancho Cucamonga, CA, USA) Model FP7 was used in all eyes. A limbus-based superotemporal conjunctival flap was created 5 mm away from the limbus, between two adjacent rectus muscles, and extended to 90&#x000b0;. The rectus muscles were identified. Before placement of the tube implant, the tube was irrigated with saline solution to open the valve mechanism. The implant&#x02019;s polypropylene body was sutured to sclera with 6-0 polyglactin sutures. The tube was fixed to the sclera with 10-0 nylon cross sutures. The anterior chamber was entered from 2 mm posterior to the corneoscleral limbus using a 23-gauge needle. The needle tract was anterior and parallel to the plane of the iris. The tube was then trimmed, so that the bevel faced the corneal endothelial surface. In group 1, the Tenon and the overlying conjunctiva were bluntly dissected at the posterior edge of the conjunctival flap and a separate Tenon flap was fashioned. The flap was pulled forward to cover the tube completely and sutured at the corneoscleral junction with 7-0 polyglactin or 10-0 nylon suture. Then, the right and left margins of the Tenon flap were sutured to the sclera with 7-0 polyglactin sutures, two on each side. At the last stage, the anterior edge of the conjunctival flap was pulled down together with the Tenon layer and sutured to the posterior conjunctival margin with continuous 7-0 or 8-0 polyglactin sutures [<xref rid="SD1" ref-type="supplementary-material">Video Clip 1</xref>].[<xref rid="R23" ref-type="bibr">23</xref>] In group 2, dura mater graft (Tutoplast<sup><inline-graphic xlink:href="IJO-72-404-g001.jpg"/></sup> dura; IOP, Inc., Costa Mesa, CA, USA) was covered over the tube and sutured to the sclera with 10-0 nylon suture. The conjunctiva was mutually sutured in a fluid-tight manner. All the eyes received subconjunctival injections of steroids and antibiotics after the operation.</p></sec><sec id="sec2-2"><title>Criteria for success</title><p>The surgical success criterion was determined as a postoperative IOP value between &#x02265;5 and &#x02264;21 mmHg, with or without antiglaucomatous therapy, measured at the last follow-up. The definition of hypotonia in this study was an IOP of 5 mmHg or less in more than two consecutive visits.</p></sec><sec id="sec2-3"><title>Statistical analysis</title><p>IBM Statistical Package for the Social Sciences (SPSS) version 22.0 (IBM Corp., Armonk, NY, USA) was used for statistical analyses. Summary values of quantitative (numeric) variables were shown as mean &#x000b1; standard deviation or median (Q1&#x02013;Q3), and summary values of qualitative (categorical) variables were shown as frequency and percentage. The conformity of quantitative variables to normal distribution was investigated using the Shapiro&#x02013;Wilk test. Since a normal distribution was not found, two independent groups were compared using the Mann&#x02013;Whitney U test. The relationship between qualitative variables was evaluated with Chi-square analysis (Fisher&#x02019;s exact test). Quantitative values obtained from IOP measurements were assessed with repeated measures analysis of variance (repeated measures ANOVA). The significance of the main effects (group and measurement times) and the interaction term (group &#x000d7; time) were evaluated. Survival rates were compared with Kaplan&#x02013;Meier analysis. Values of <italic toggle="yes">P</italic> &#x0003c; 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><p>A total of 44 eyes of 44 patients were included in the study, and 20 eyes in group 1 and 24 eyes in group 2 were evaluated. <xref rid="IJO.IJO_772_23-T1" ref-type="table">Table 1</xref> shows the demographic characteristics of the patients.</p><table-wrap position="float" id="IJO.IJO_772_23-T1"><label>Table 1</label><caption><p>Demographic characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients (<italic toggle="yes">n</italic>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">60.5&#x000b1;15.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">54.8&#x000b1;23.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.361<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (F/M)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11/9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7/17</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.002<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Follow-up time (months)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16.8&#x000b1;13.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">27.3&#x000b1;16.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.027<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Systemic disorders</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;DM</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 (30%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="3" colspan="1">0.003<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;HT</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (10%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 (20.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;DM + HT</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 (30%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (8.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Glaucoma subtype</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;POAG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;SG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 (25%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (12.5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="4" colspan="1">0.005<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;NVG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11 (55%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7 (29.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;XFG</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 (20%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Congenital</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (12.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Previous surgery</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PHACO</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8 (40%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 (25%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="4" colspan="1">0.369<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">TRAB</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (10%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5 (20.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PPV</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 (20%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">PHACO + TRAB</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (10%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (12.5%)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p><sup>a</sup>Independent samples <italic toggle="yes">t</italic>-test. <sup>b</sup>Chi-squared test. DM=diabetes mellitus, HT=arterial hypertension, NVG=neovascular glaucoma, PHACO=phacoemulsification surgery, POAG=primary open-angle glaucoma, PPV=pars plana vitrectomy, SG=secondary glaucoma, TRAB=trabeculectomy surgery, XFG=exfoliation glaucoma</p></fn></table-wrap-foot></table-wrap><p>At the end of the mean follow-up period of 22.6 &#x000b1; 10.6 months, the success rates were 95% in group 1 and 96% in group 2. No difference between the groups was detected with regard to postoperative complications, postoperative antiglaucoma medications onset time, need for needling, tube exposure, encapsulation, and presence of HP. (P-values: 0.47, 0.86, 0.12, 0.27, 0.9, 0.51 respectively) [<xref rid="IJO.IJO_772_23-T2" ref-type="table">Table 2</xref>]. The IOP values at the last visit were 15.2 &#x000b1; 4.1 in group 1 and 14.7 &#x000b1; 4.8 in group 2. The IOP reduction rates also showed no significant difference between the groups [<xref rid="IJO.IJO_772_23-T3" ref-type="table">Table 3</xref>].</p><table-wrap position="float" id="IJO.IJO_772_23-T2"><label>Table 2</label><caption><p>Postoperative complications</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hypertensive phase (<italic toggle="yes">n</italic>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8 (40%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 (50%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.507</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative complications (total) (<italic toggle="yes">n</italic>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7 (35%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11 (45.8%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.467</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyphema</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (8.3%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.662</td></tr><tr><td align="left" rowspan="1" colspan="1">Iris&#x02013;lens touch</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2 (10%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 (16.7%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.521</td></tr><tr><td align="left" rowspan="1" colspan="1">Choroidal detachment</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3 (15%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 (16.7%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Tube exposure</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.268</td></tr><tr><td align="left" rowspan="1" colspan="1">Tube occluded by vitreous</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.356</td></tr><tr><td align="left" rowspan="1" colspan="1">Encapsulation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (5%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1 (4.2%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.895</td></tr><tr><td align="left" rowspan="1" colspan="1">Needling requirement</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4 (20%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10 (41.7%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypotonia</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>Statistical analysis was conducted with the Chi-square test</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="IJO.IJO_772_23-T3"><label>Table 3</label><caption><p>Intraocular pressure reduction rates between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Pre-op IOP (mmHg)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">31.2&#x000b1;8.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33.9&#x000b1;7.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Post-op first IOP (mmHg)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11.6&#x000b1;5.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12.4&#x000b1;6.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Post-op last IOP (mmHg)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15.2&#x000b1;4.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">14.7&#x000b1;4.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="TF-F3"><p>Statistical analysis was conducted with the Pearson Chi-square test. IOP=intraocular pressure</p></fn></table-wrap-foot></table-wrap><p>Analysis of the success rates according to the last examination pressure and HP in the first 6 months postoperatively based on previous surgery history before trabeculectomy revealed no significant differences (<italic toggle="yes">P</italic>-values: 1 and 0.39, respectively). No statistically significant differences were found in the comparative analysis of these same parameters with the type of previous surgery (<italic toggle="yes">P</italic>-values: 0.36 and 0.47, respectively). In terms of surgical techniques, no significant difference was observed in the statistical analyses of postoperative HP and antiglaucomatous onset time (<italic toggle="yes">P</italic>-values: 0.36 and 0.89, respectively). Group 2 showed a higher HP percentage, but no statistically significant difference was detected when evaluating postoperative complications, success according to the last examination pressure, and HP in the first 6 months according to the glaucoma type (<italic toggle="yes">P</italic>-values: 0.92, 0.71, and 0.39, respectively). Although the need for needling was seen more in the dura mater covering technique, this was not statistically significant (<italic toggle="yes">P</italic> = 0.124). There was no difference in survival rate over time between the two groups (<italic toggle="yes">P</italic> values in log rank: 0.968, Breslow: 0.611, and Tarone&#x02013;Ware: 0.718). It was estimated that hypertensive recurrence would not occur for a median (95% confidence interval [CI], Low&#x02013;Upp) of 24 (21.92&#x02013;26.08) months in patients with Tenon duplication and 16 (8.54&#x02013;23.46) months in patients with dura mater covering technic [<xref rid="IJO.IJO_772_23-F1" ref-type="fig">Fig. 1</xref>]. No vision loss was observed in any of the patients at their final follow-up.</p><fig position="float" id="IJO.IJO_772_23-F1"><label>Figure 1</label><caption><p>Means and medians for survival time with Kaplan&#x02013;Meier analysis</p></caption><graphic xlink:href="IJO-72-404-g002" position="float"/></fig></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>Filtering surgery is usually the first surgical option for glaucoma treatment. GDDs, such as AGV, are often an option available to patients with glaucoma refractory to filtering surgeries.[<xref rid="R24" ref-type="bibr">24</xref>] Although GDDs have been used frequently for years to reduce eye pressure, complications of AGV, such as tube exposure, choroidal detachment, hyphema, iris&#x02013;lens touch, and encapsulation, can occur. Ou <italic toggle="yes">et al</italic>.[<xref rid="R25" ref-type="bibr">25</xref>] reported that the most common complication after AGV implantation in patients with primary congenital glaucoma was tube&#x02013;corneal touch. Tube exposure is also a significant AGV implantation problem, as it leads to both mechanical damage and inflammation-mediated melting of the self-tissue or the donor graft. Inferiorly placed implants, diabetes, presence of prior inflammation, previous ocular surgery, and younger age are well-known risk factors for tube exposure associated with GDDs.[<xref rid="R19" ref-type="bibr">19</xref><xref rid="R26" ref-type="bibr">26</xref>] In addition, there are studies claiming that previous eye surgery is not a risk factor for exposure.[<xref rid="R27" ref-type="bibr">27</xref>] Untreated cases of tube exposure are well known to lead to possible endophthalmitis, with a poor prognosis. Recognizing these complications of AGV tube, we investigated the methods and modifications that could potentially prevent exposure and maintain IOP reduction during the postoperative period.</p><p>Although a number of surgical methods have been described to prevent tube exposure, such as placement of patch graft (e.g., fascia lata, pericardium, donor sclera, or lyophilized dura mater), lengthy scleral tunnel, and/or duplication and advancement of Tenon&#x02019;s tissue, there is no consensus on the best approach. Tamcelik <italic toggle="yes">et al</italic>.[<xref rid="R23" ref-type="bibr">23</xref>] divided their patients into three groups according to the covering techniques used during AGV implantation. They did not see any exposure in the Tenon duplication group and claimed it to be the safest method. Gedar Totuk <italic toggle="yes">et al</italic>.[<xref rid="R28" ref-type="bibr">28</xref>] tried to prevent AGV tube exposure by creating a long scleral flap augmented with Tenon advancement and duplication; they had no exposure in the 2-year follow-up. Since an exposure case was seen in the Tenon duplication group in our study, it can be thought that adding the long scleral flap technique to the Tenon duplication technique may have an effect on reducing exposure. However, long scleral tunnel or scleral flap techniques are not ideal for all cases, such as in patients who have previously undergone multiple ocular surgeries and therefore have very thin scleral tissue. In those patients, the graft material would be combined with Tenon duplication technique to prevent tube exposure. Our study showed no significant difference between the two techniques in terms of surgical success and complications. The finding that there was no statistically significant difference in the IOP-lowering effect of both techniques and in the incidence of HP in our study is a valuable new result.</p><p>There are over 1000 articles about AGV in the literature, yet there is no clear consensus on the failure criteria of AGV implantation. Although some authors consider the requirement of needling as a failure, there are some who consider the lack of regulation of IOP despite needling as a failure. For example, in the review of Riva <italic toggle="yes">et al</italic>.[<xref rid="R29" ref-type="bibr">29</xref>] and the study of Eibschitz-Tsimhoni <italic toggle="yes">et al</italic>.,[<xref rid="R30" ref-type="bibr">30</xref>] cases whose IOP could not be controlled despite medical treatment and 5-FU injection together with needling were considered unsuccessful. We do not consider needling as a failure, as all of the patients in our study who needed needling achieved the desired IOP values after needling and the values were found to be within normal ranges in their follow-up.</p><p>The limitations of our study include its retrospective nature, nonrandomized design, and follow-up loss at later time points. The selection bias due to the retrospective nature of the study could affect the reliability and validity. Although differences between the groups, especially in terms of gender, follow-up time, systemic disease, and glaucoma subtype, may affect the outcome of the study, we think that the acceptability of the study continues because there was no significant difference between the two groups. A possibility of overestimating surgical failure exists, as patients with more severe pathologies may continue to visit the ophthalmologist for longer periods. An underestimation of surgical failure is also possible due to the short follow-up time. The study&#x02019;s strengths include the fact that all the operations were performed at a single hospital by two qualified surgeons. Comparison of the Tenon duplication technique and the dura mater covering technique also had not been done before.</p><p>In conclusion, the use of special allograft materials, which can prolong the operation time and increase the patient&#x02019;s economic burden, may not be necessary in AGV implantation surgery, except in special cases.</p><sec id="sec2-4"><title>Patient consent for publication</title><p>Not applicable.</p></sec><sec id="sec2-5"><title>Ethics approval</title><p>This study was approved by the ethics committee of Eski&#x0015f;ehir Osmangazi University (approval ID: 04.10.2022/30), and the study complied with the tenets of the Declaration of Helsinki.</p></sec><sec sec-type="funding-statement" id="sec2-6"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" id="sec2-7"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec><sec sec-type="supplementary-material"><title>Video available on: <ext-link xlink:href="https://journals.lww.com/ijo" ext-link-type="uri">https://journals.lww.com/ijo</ext-link></title><supplementary-material id="SD1" position="float" content-type="local-data"><media xlink:href="IJO-72-404-v001.mp4" id="d67e800" position="anchor" mimetype="video" mime-subtype="mp4"/></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leske</surname><given-names>MC</given-names></name>
<name><surname>Heijl</surname><given-names>A</given-names></name>
<name><surname>Hussein</surname><given-names>M</given-names></name>
<name><surname>Bengtsson</surname><given-names>B</given-names></name>
<name><surname>Hyman</surname><given-names>L</given-names></name>
<name><surname>Komaroff</surname><given-names>E</given-names></name>
<etal/></person-group><article-title>Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial</article-title><source>Arch Ophthalmol</source><year>2003</year><volume>121</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">12523884</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>MO</given-names></name>
<name><surname>Beiser</surname><given-names>JA</given-names></name>
<name><surname>Brandt</surname><given-names>JD</given-names></name>
<name><surname>Heuer</surname><given-names>DK</given-names></name>
<name><surname>Higginbotham</surname><given-names>EJ</given-names></name>
<name><surname>Johnson</surname><given-names>CA</given-names></name>
<etal/></person-group><article-title>The Ocular hypertension treatment study: Baseline factors that predict the onset of primary open-angle glaucoma</article-title><source>Arch Ophthalmol</source><year>2002</year><volume>120</volume><fpage>714</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12049575</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group; Gordon</surname><given-names>MO</given-names></name>
<name><surname>Torri</surname><given-names>V</given-names></name>
<name><surname>Miglior</surname><given-names>S</given-names></name>
<name><surname>Beiser</surname><given-names>JA</given-names></name>
<etal/></person-group><article-title>Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><fpage>10</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17095090</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nouri-Mahdavi</surname><given-names>K</given-names></name>
<name><surname>Hoffman</surname><given-names>D</given-names></name>
<name><surname>Coleman</surname><given-names>AL</given-names></name>
<name><surname>Liu</surname><given-names>G</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
<name><surname>Gaasterland</surname><given-names>D</given-names></name>
<etal/></person-group><article-title>Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study</article-title><source>Ophthalmology</source><year>2004</year><volume>111</volume><fpage>1627</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15350314</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Green</surname><given-names>CM</given-names></name>
<name><surname>Kearns</surname><given-names>LS</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Barbour</surname><given-names>JM</given-names></name>
<name><surname>Wilkinson</surname><given-names>RM</given-names></name>
<name><surname>Ring</surname><given-names>MA</given-names></name>
<etal/></person-group><article-title>How significant is a family history of glaucoma? Experience from the Glaucoma Inheritance Study in Tasmania</article-title><source>Clin Exp Ophthalmol</source><year>2007</year><volume>35</volume><fpage>793</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18173405</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillunat</surname><given-names>LE</given-names></name>
<name><surname>Stodtmeister</surname><given-names>R</given-names></name>
<name><surname>Marquardt</surname><given-names>R</given-names></name>
<name><surname>Mattern</surname><given-names>A</given-names></name></person-group><article-title>Ocular perfusion pressures in different types of glaucoma</article-title><source>Int Ophthalmol</source><year>1989</year><volume>13</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">2744953</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quaranta</surname><given-names>L</given-names></name>
<name><surname>Katsanos</surname><given-names>A</given-names></name>
<name><surname>Russo</surname><given-names>A</given-names></name>
<name><surname>Riva</surname><given-names>I</given-names></name></person-group><article-title>24-hour intraocular pressure and ocular perfusion pressure in glaucoma</article-title><source>Surv Ophthalmol</source><year>2013</year><volume>58</volume><fpage>26</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">23217586</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quaranta</surname><given-names>L</given-names></name>
<name><surname>Manni</surname><given-names>G</given-names></name>
<name><surname>Donato</surname><given-names>F</given-names></name>
<name><surname>Bucci</surname><given-names>MG</given-names></name></person-group><article-title>The effect of increased intraocular pressure on pulsatile ocular blood flow in low tension glaucoma</article-title><source>Surv Ophthalmol</source><year>1994</year><volume>38</volume><issue>Suppl</issue><fpage>S177</fpage><lpage>81</lpage><comment>; discussion S182</comment><pub-id pub-id-type="pmid">7940140</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rulli</surname><given-names>E</given-names></name>
<name><surname>Biagioli</surname><given-names>E</given-names></name>
<name><surname>Riva</surname><given-names>I</given-names></name>
<name><surname>Gambirasio</surname><given-names>G</given-names></name>
<name><surname>De Simone</surname><given-names>I</given-names></name>
<name><surname>Floriani</surname><given-names>I</given-names></name>
<etal/></person-group><article-title>Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: A systematic review and meta-analysis</article-title><source>JAMA Ophthalmol</source><year>2013</year><volume>131</volume><fpage>1573</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">24158640</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prum</surname><given-names>BE</given-names><suffix>Jr</suffix></name>
<name><surname>Rosenberg</surname><given-names>LF</given-names></name>
<name><surname>Gedde</surname><given-names>SJ</given-names></name>
<name><surname>Mansberger</surname><given-names>SL</given-names></name>
<name><surname>Stein</surname><given-names>JD</given-names></name>
<name><surname>Moroi</surname><given-names>SE</given-names></name>
<etal/></person-group><article-title>Primary Open-angle glaucoma preferred practice pattern(&#x000ae;) guidelines</article-title><source>Ophthalmology</source><year>2016</year><volume>123</volume><fpage>41</fpage><lpage>111</lpage></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cairns</surname><given-names>JE</given-names></name></person-group><article-title>Trabeculectomy. Preliminary report of a new method</article-title><source>Am J Ophthalmol</source><year>1968</year><volume>66</volume><fpage>673</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">4891876</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilensky</surname><given-names>JT</given-names></name>
<name><surname>Chen</surname><given-names>TC</given-names></name></person-group><article-title>Long-term results of trabeculectomy in eyes that were initially successful</article-title><source>Trans Am Ophthalmol Soc</source><year>1996</year><volume>94</volume><fpage>147</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">8981694</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bevin</surname><given-names>TH</given-names></name>
<name><surname>Molteno</surname><given-names>AC</given-names></name>
<name><surname>Herbison</surname><given-names>P</given-names></name></person-group><article-title>Otago glaucoma surgery outcome study: Long-term results of 841 trabeculectomies</article-title><source>Clin Exp Ophthalmol</source><year>2008</year><volume>36</volume><fpage>731</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19128377</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landers</surname><given-names>J</given-names></name>
<name><surname>Martin</surname><given-names>K</given-names></name>
<name><surname>Sarkies</surname><given-names>N</given-names></name>
<name><surname>Bourne</surname><given-names>R</given-names></name>
<name><surname>Watson</surname><given-names>P</given-names></name></person-group><article-title>A twenty-year follow-up study of trabeculectomy: Risk factors and outcomes</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><fpage>694</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">22196977</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takihara</surname><given-names>Y</given-names></name>
<name><surname>Inatani</surname><given-names>M</given-names></name>
<name><surname>Fukushima</surname><given-names>M</given-names></name>
<name><surname>Iwao</surname><given-names>K</given-names></name>
<name><surname>Iwao</surname><given-names>M</given-names></name>
<name><surname>Tanihara</surname><given-names>H</given-names></name></person-group><article-title>Trabeculectomy with mitomycin C for neovascular glaucoma: Prognostic factors for surgical failure</article-title><source>Am J Ophthalmol</source><year>2009</year><volume>147</volume><fpage>912</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19195639</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iwao</surname><given-names>K</given-names></name>
<name><surname>Inatani</surname><given-names>M</given-names></name>
<name><surname>Seto</surname><given-names>T</given-names></name>
<name><surname>Takihara</surname><given-names>Y</given-names></name>
<name><surname>Ogata-Iwao</surname><given-names>M</given-names></name>
<name><surname>Okinami</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Long-term outcomes and prognostic factors for trabeculectomy with mitomycin C in eyes with uveitic glaucoma: A retrospective cohort study</article-title><source>J Glaucoma</source><year>2014</year><volume>23</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">22895522</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gedde</surname><given-names>SJ</given-names></name>
<name><surname>Schiffman</surname><given-names>JC</given-names></name>
<name><surname>Feuer</surname><given-names>WJ</given-names></name>
<name><surname>Herndon</surname><given-names>LW</given-names></name>
<name><surname>Brandt</surname><given-names>JD</given-names></name>
<name><surname>Budenz</surname><given-names>DL</given-names></name>
<etal/></person-group><article-title>Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up</article-title><source>Am J Ophthalmol</source><year>2012</year><volume>153</volume><fpage>789</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">22245458</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>S</given-names></name>
<name><surname>Pasquale</surname><given-names>LR</given-names></name></person-group><article-title>Glaucoma drainage devices: A review of the past, present, and future</article-title><source>Semin Ophthalmol</source><year>2010</year><volume>25</volume><fpage>265</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">21091010</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaku</surname><given-names>M</given-names></name>
<name><surname>Netland</surname><given-names>PA</given-names></name>
<name><surname>Ishida</surname><given-names>K</given-names></name>
<name><surname>Rhee</surname><given-names>DJ</given-names></name></person-group><article-title>Risk factors for tube exposure as a late complication of glaucoma drainage implant surgery</article-title><source>Clin Ophthalmol</source><year>2016</year><volume>10</volume><fpage>547</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">27099461</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakur</surname><given-names>S</given-names></name>
<name><surname>Ichhpujani</surname><given-names>P</given-names></name>
<name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Grafts in glaucoma surgery: A review of the literature</article-title><source>Asia Pac J Ophthalmol (Phila)</source><year>2017</year><volume>6</volume><fpage>469</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">28379649</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papadopoulos</surname><given-names>K</given-names></name>
<name><surname>Schroder</surname><given-names>FM</given-names></name>
<name><surname>Sekundo</surname><given-names>W</given-names></name></person-group><article-title>Long-term surgical outcomes of two different Ahmed Valve implantation techniques in refractory glaucoma: Scleral flap vs scleral tunnel</article-title><source>Eur J Ophthalmol</source><year>2023</year><volume>33</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">35473453</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>VP</given-names></name>
<name><surname>Azuara-Blanco</surname><given-names>A</given-names></name>
<name><surname>Netland</surname><given-names>PA</given-names></name>
<name><surname>Lesk</surname><given-names>MR</given-names></name>
<name><surname>Arcieri</surname><given-names>ES</given-names></name></person-group><article-title>Efficacy and safety of adjunctive mitomycin C during Ahmed Glaucoma Valve implantation: A prospective randomized clinical trial</article-title><source>Ophthalmology</source><year>2004</year><volume>111</volume><fpage>1071</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15177955</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamcelik</surname><given-names>N</given-names></name>
<name><surname>Ozkok</surname><given-names>A</given-names></name>
<name><surname>Sarici</surname><given-names>AM</given-names></name>
<name><surname>Atalay</surname><given-names>E</given-names></name>
<name><surname>Yetik</surname><given-names>H</given-names></name>
<name><surname>Gungor</surname><given-names>K</given-names></name></person-group><article-title>Tenon advancement and duplication technique to prevent postoperative Ahmed valve tube exposure in patients with refractory glaucoma</article-title><source>Jpn J Ophthalmol</source><year>2013</year><volume>57</volume><fpage>359</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">23702610</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayyala</surname><given-names>RS</given-names></name>
<name><surname>Zurakowski</surname><given-names>D</given-names></name>
<name><surname>Smith</surname><given-names>JA</given-names></name>
<name><surname>Monshizadeh</surname><given-names>R</given-names></name>
<name><surname>Netland</surname><given-names>PA</given-names></name>
<name><surname>Richards</surname><given-names>DW</given-names></name>
<etal/></person-group><article-title>A clinical study of the Ahmed glaucoma valve implant in advanced glaucoma</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>1968</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">9787371</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ou</surname><given-names>Y</given-names></name>
<name><surname>Yu</surname><given-names>F</given-names></name>
<name><surname>Law</surname><given-names>SK</given-names></name>
<name><surname>Coleman</surname><given-names>AL</given-names></name>
<name><surname>Caprioli</surname><given-names>J</given-names></name></person-group><article-title>Outcomes of Ahmed glaucoma valve implantation in children with primary congenital glaucoma</article-title><source>Arch Ophthalmol</source><year>2009</year><volume>127</volume><fpage>1436</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19901208</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souza</surname><given-names>C</given-names></name>
<name><surname>Tran</surname><given-names>DH</given-names></name>
<name><surname>Loman</surname><given-names>J</given-names></name>
<name><surname>Law</surname><given-names>SK</given-names></name>
<name><surname>Coleman</surname><given-names>AL</given-names></name>
<name><surname>Caprioli</surname><given-names>J</given-names></name></person-group><article-title>Long-term outcomes of Ahmed glaucoma valve implantation in refractory glaucomas</article-title><source>Am J Ophthalmol</source><year>2007</year><volume>144</volume><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">17916318</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>CK</given-names></name>
<name><surname>Ma</surname><given-names>KT</given-names></name>
<name><surname>Hong</surname><given-names>YJ</given-names></name>
<name><surname>Kim</surname><given-names>CY</given-names></name></person-group><article-title>Long-term clinical outcomes of Ahmed valve implantation in patients with refractory glaucoma</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0187533</fpage><pub-id pub-id-type="pmid">29095931</pub-id>
</element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gedar Totuk</surname><given-names>OM</given-names></name>
<name><surname>Kabadayi</surname><given-names>K</given-names></name>
<name><surname>Colakoglu</surname><given-names>A</given-names></name>
<name><surname>Ekizoglu</surname><given-names>N</given-names></name>
<name><surname>Aykan</surname><given-names>U</given-names></name></person-group><article-title>A novel surgical technique for prevention of Ahmed glaucoma valve tube exposure: Long scleral flap augmented with Tenon advancement and duplication</article-title><source>BMC Ophthalmol</source><year>2018</year><volume>18</volume><fpage>226</fpage><pub-id pub-id-type="pmid">30170565</pub-id>
</element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riva</surname><given-names>I</given-names></name>
<name><surname>Roberti</surname><given-names>G</given-names></name>
<name><surname>Oddone</surname><given-names>F</given-names></name>
<name><surname>Konstas</surname><given-names>AG</given-names></name>
<name><surname>Quaranta</surname><given-names>L</given-names></name></person-group><article-title>Ahmed glaucoma valve implant: Surgical technique and complications</article-title><source>Clin Ophthalmol</source><year>2017</year><volume>11</volume><fpage>357</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">28255226</pub-id>
</element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eibschitz-Tsimhoni</surname><given-names>M</given-names></name>
<name><surname>Schertzer</surname><given-names>RM</given-names></name>
<name><surname>Musch</surname><given-names>DC</given-names></name>
<name><surname>Moroi</surname><given-names>SE</given-names></name></person-group><article-title>Incidence and management of encapsulated cysts following Ahmed glaucoma valve insertion</article-title><source>J Glaucoma</source><year>2005</year><volume>14</volume><fpage>276</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15990607</pub-id>
</element-citation></ref></ref-list></back></article>